RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening...
As filed with the Securities and Exchange Commission on November 8...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
CeD LA 3001 trial doses first patient in historic Phase 3 celiac disease trial RALEIGH, N.C., Aug. 13, 2019...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...
Company is exploring potential strategic opportunities and non-dilutive sources of capital, and partnerships...
Innovate undertakes succession planning for a chief executive officer Finance team strengthened and well...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
As filed with the Securities and Exchange Commission on...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.